Severe Eosinophilic Asthma is a debilitating respiratory condition marked by persistent airway inflammation due to elevated eosinophil levels. It affects 5-10% of asthma patients and is resistant to standard treatments.
Hightower Clinicals is investigating a novel drug to target its mechanisms. This innovative research offers hope for better management and symptom alleviation, potentially transforming the lives of those affected.
Hightower aims to address the unmet medical needs of severe eosinophilic asthma patients, providing a promising avenue for improved treatment outcomes and enhanced quality of life.
*All study procedures and study-related treatment, including the investigational drug, are free of cost, and insurance is not required to participate.*
